Rosa Biotech

Rosa Biotech is redefining biosensing. We are enabling previously intractable challenges in early disease diagnosis and industrial biotechnology to be addressed accurately and at scale.

Our patent-pending technology builds upon and extends the pioneering protein design work of Prof. Dek Woolfson and his team at the University of Bristol’s Synthetic Biology Research Centre, BrisSynBio. By combining this with advanced machine-learning techniques, we offer a powerful platform capable of being trained to address numerous complex biosensing problems.

Rosa was incorporated in early 2019, following 12 months of preparation and detailed planning. The company is backed by a team of experienced, high-profile business angels. These include the founders of Ziylo, the biosensing company recently acquired by Novo Nordisk for up to $800 million, and Cramer, the systems technology company acquired by Amdocs for $425M.

We are based at the Unit DX biosciences hub in the heart of Bristol. Conveniently located near Bristol Temple Meads station, the hub is home to over 20 science-driven companies and provides a melting pot of academic researchers, startup and spinout companies, investors and support services.